The longevity-research community in the UAE has matured rapidly. Investigators in Dubai, Abu Dhabi, and Sharjah are moving beyond single-compound curiosity and into structured research stacks that target specific hallmarks of biological aging: declining GH/IGF-1 output, accumulating visceral fat, hepatic lipid accumulation, and systemic low-grade inflammation. Tesamorelin sits at the intersection of all four. It is not a growth hormone itself — it is a synthetic analog of endogenous growth-hormone-releasing hormone (GHRH 1-44) that restores the upstream pulsatile signal the pituitary uses to make GH. That distinction matters enormously for research design. REVIVE LAB UAE supplies HPLC-verified, lot-COA, cold-chain dispatched tesamorelin across all 7 emirates, and this post is the reference document UAE investigators have been asking for.
GH secretion declines by approximately 14% per decade after the third decade of life — a trajectory the endocrinology literature calls somatopause. The downstream consequence is a parallel fall in IGF-1 (insulin-like growth factor 1), the hepatic-derived peptide that mediates many of GH's tissue-level effects: protein synthesis, lipolysis, cellular repair, and neurotrophin support. By the fifth decade, many individuals show IGF-1 levels in the lower quartile of the reference range even when no frank pituitary pathology exists.
The straightforward intervention — exogenous GH — bypasses the pituitary feedback entirely and produces non-physiological, non-pulsatile GH exposure. Investigators working in anti-aging and longevity research have increasingly shifted interest toward upstream GHRH stimulation precisely because it preserves the pulsatile architecture of GH release, keeps the hypothalamic-pituitary axis intact, and allows negative feedback to operate. Tesamorelin is the most clinically characterised GHRH analog in existence, with four major peer-reviewed publications backing its metabolic and IGF-1 effects.
The pivotal evidence comes from two research groups whose combined publication record spans NEJM, JAMA, and The Lancet HIV — the three journals UAE investigators are most likely to cite when designing a research protocol.
The Falutz group enrolled 412 subjects in a randomised, double-blind, placebo-controlled trial of tesamorelin in HIV-associated lipodystrophy (Falutz et al., N Engl J Med, 2007). At the primary endpoint, tesamorelin at 2 mg/day SC produced a 15-18% reduction in visceral adipose tissue (VAT) versus placebo as measured by CT cross-section, alongside a ~50% rise in IGF-1 from baseline. Critically, IGF-1 levels remained within the normal physiological range — an observation the authors specifically noted as differentiating tesamorelin from supraphysiologic GH exposure.
The 2010 extension (Falutz et al., J Clin Endocrinol Metab, 26-week continuation) confirmed that the VAT reduction and IGF-1 elevation were durable: investigators who maintained tesamorelin sustained the visceral fat deficit, while the placebo-switched group showed rapid VAT rebound — a rebound that has since been interpreted as evidence that tesamorelin's effects are active and ongoing rather than structural.
Stanley and colleagues at Massachusetts General Hospital extended the tesamorelin evidence base into non-alcoholic fatty liver disease (NAFLD) in an HIV cohort (Stanley et al., JAMA, 2014). At 12 weeks, tesamorelin reduced liver fat by 32% relative to placebo as measured by MRS (magnetic resonance spectroscopy). The 2019 Lancet HIV paper extended follow-up to 12 months and confirmed the liver-fat benefit was sustained, with secondary signals on hepatic fibrosis markers that are now part of ongoing non-HIV longevity research inquiries.
| Study | Journal / Year | N | Key Outcome |
|---|---|---|---|
| Falutz et al. | NEJM 2007 | 412 | VAT −15-18%; IGF-1 +~50% (within normal range) |
| Falutz et al. | J Clin Endocrinol Metab 2010 | Extension | VAT reduction durable; rapid rebound on discontinuation |
| Stanley et al. | JAMA 2014 | RCT | Liver fat −32% vs placebo at 12 weeks (MRS) |
| Stanley et al. | Lancet HIV 2019 | 12-month RCT | Liver fat reduction sustained; fibrosis marker signals |
For UAE investigators designing longevity-focused research protocols, the combined read is this: tesamorelin produces a physiological IGF-1 elevation, simultaneously reduces two of the most mechanistically relevant aging biomarkers (visceral adiposity and hepatic lipid accumulation), and does so through a mechanism that does not suppress endogenous GHRH signalling the way exogenous GH would. That is a narrow but defensible research rationale.
The anti-aging stack most commonly assembled by UAE research investigators pairs tesamorelin with at least one complementary peptide targeting a distinct pathway. The most frequently cited companion is GHK-Cu (copper glycine-histidine-lysine tripeptide) — a naturally occurring plasma peptide that falls sharply with age and has been studied for its roles in extracellular matrix remodelling, antioxidant gene upregulation (via Nrf2), and wound-healing signalling.
The mechanistic rationale for stacking tesamorelin with GHK-Cu is non-overlapping pathway coverage:
Investigators interested in a more comprehensive metabolic longevity protocol have also placed tesamorelin alongside compounds targeting the GIP/GLP-1/glucagon triagonist axis, though that stack represents a different research question and a separate compound class. For the purposes of this document, the REVIVE LAB UAE research-use focus is on tesamorelin as the GHRH-axis anchor of an anti-aging stack.
The Falutz 2007 NEJM trial used 2 mg/day administered subcutaneously, and that dose has become the de facto reference point for tesamorelin research protocols. The 2010 extension maintained the same 2 mg/day schedule. Stanley's JAMA 2014 work also used 2 mg/day. A subset of investigators — particularly those combining tesamorelin with other GH-axis-active compounds — have used 1 mg/day as the research-context starting point, reducing IGF-1 overshoot risk in populations that already show moderate endogenous IGF-1 levels.
REVIVE LAB UAE stocks tesamorelin in two vial sizes: 5 mg and 10 mg lyophilized powder. Both are reconstituted with bacteriostatic water immediately before use. The reconstitution math for common research-context schedules is shown below.
| Vial Size | BAC Water Added | Concentration | Volume for 1 mg dose | Volume for 2 mg dose |
|---|---|---|---|---|
| Tesamorelin 5 mg | 2 mL | 2.5 mg/mL | 0.4 mL (40 IU) | 0.8 mL (80 IU) |
| Tesamorelin 5 mg | 1 mL | 5 mg/mL | 0.2 mL (20 IU) | 0.4 mL (40 IU) |
| Tesamorelin 10 mg | 2 mL | 5 mg/mL | 0.2 mL (20 IU) | 0.4 mL (40 IU) |
| Tesamorelin 10 mg | 4 mL | 2.5 mg/mL | 0.4 mL (40 IU) | 0.8 mL (80 IU) |
The 10 mg vial is the more economical choice for investigators running protocols aligned with the Stanley 2014 or 2019 timelines (12 weeks to 12 months at 2 mg/day). The 5 mg vial suits shorter exploratory research windows or protocols where dosing is 1 mg/day. Both sizes ship from REVIVE LAB UAE in validated cold-chain packaging that holds 2-8°C through any UAE summer transit.
Tesamorelin's primary research biomarker is serum IGF-1. In the Falutz 2007 trial, IGF-1 was the headline secondary endpoint and increased approximately 50% from baseline — rising into, but not beyond, the upper-normal physiological range. For longevity-focused research protocols, IGF-1 measured at baseline and at 4, 8, and 12 weeks is the standard tracking cadence used in the published literature.
Secondary biomarkers tracked across the Stanley and Falutz datasets include:
Investigators running tesamorelin alongside GHK-Cu or other peptides UAE research stacks typically capture these biomarkers at baseline and at the 12-week mark minimum, with optional 6-week interim bloods for protocols running at the 2 mg/day dose.
The peptides UAE supply landscape has fragmented quickly as demand has grown. Most overseas suppliers — regardless of what their websites claim — cannot guarantee cold-chain integrity through DXB customs and summer tarmac temperatures. REVIVE LAB UAE is a Dubai-based operation: vials are held locally, dispatched by refrigerated courier, and arrive at the investigator's lab or facility without a transcontinental temperature excursion in between.
Every tesamorelin batch supplied by REVIVE LAB UAE is:
For researchers who prefer digital settlement, REVIVE LAB UAE now accepts USDT (TRC20) via Binance Pay with a 5% pre-pay discount applied at checkout — making it one of the few peptides UAE suppliers to offer verified USDT crypto pay Dubai. Cash on delivery remains available across all 7 emirates for investigators who prefer the traditional UAE payment model.
Researchers based anywhere in the UAE can order tesamorelin UAE with confidence. REVIVE LAB UAE operates same-day dispatch out of Dubai, covering the full emirate on most weekdays. For the six remaining emirates, the standard window is 18-24 hours from order confirmation.
| Emirate / Area | Delivery Window | Cash on Delivery | Cold-Chain |
|---|---|---|---|
| Dubai (Marina, JBR, Business Bay, DIFC, Downtown, Palm, JVC, Jumeirah) | Same-day, 4-8 hours | Yes | Yes |
| Abu Dhabi (Corniche, Yas, Saadiyat, Reem Island) | Next-day, 18-24 hours | Yes | Yes |
| Sharjah | Same-day / next-day, 8-18 hours | Yes | Yes |
| Ajman | Next-day, 18-24 hours | Yes | Yes |
| Ras Al Khaimah | Next-day, 18-24 hours | Yes | Yes |
| Fujairah | Next-day, 24 hours | Yes | Yes |
| Umm Al Quwain | Next-day, 18-24 hours | Yes | Yes |
A researcher in Business Bay or DIFC ordering tesamorelin same day Dubai before the afternoon cut-off typically receives cold-packed vials by early evening. The broader research community across Abu Dhabi, Sharjah, RAK, Fujairah, Ajman, and UAQ is served within the tesamorelin 24h delivery window. This is what a genuinely UAE-based peptides UAE supplier looks like in practice.
REVIVE LAB UAE stocks tesamorelin in 5 mg and 10 mg lyophilized vials — those are the only two sizes available, and no other strengths should be assumed stocked. Research-context dosing referenced across the Falutz 2007 NEJM trial and the Stanley 2014 JAMA protocol used 1 mg/day and 2 mg/day schedules. Investigators running a shorter exploratory research window often opt for the 5 mg vial; those aligning with the 12-week or 12-month Stanley-protocol timelines at 2 mg/day will find the 10 mg vial more practical to avoid mid-protocol restocking. Both sizes are HPLC-verified, lot-COA-backed, and available for tesamorelin same day Dubai delivery or 24h delivery across all 7 emirates.
Yes. REVIVE LAB UAE dispatches tesamorelin same-day in Dubai for orders placed before the daily cut-off, with refrigerated courier delivery to Dubai Marina, JBR, Business Bay, DIFC, JVC, Downtown, Palm Jumeirah, Jumeirah, Emirates Hills, and surrounding areas typically within 4-8 hours. Abu Dhabi, Sharjah, Ajman, Ras Al Khaimah, Fujairah, and Umm Al Quwain are covered within 18-24 hours. All shipments use validated cold-chain insulated packaging and plain, unbranded outer cartons. Cash on delivery Dubai and across all 7 emirates is the default payment option.
REVIVE LAB UAE accepts cash on delivery across all 7 UAE emirates — no upfront payment is required for local orders. For researchers who prefer fully digital settlement, USDT (TRC20) via Binance Pay is accepted with a 5% pre-pay discount, confirmed by WhatsApp transaction ID. Both payment routes come with the same HPLC-verified, lot-COA tesamorelin 5 mg and 10 mg vials dispatched same-day from Dubai in cold-chain packaging.